Hyloris Pharmaceuticals SA
XBRU:HYL

Watchlist Manager
Hyloris Pharmaceuticals SA Logo
Hyloris Pharmaceuticals SA
XBRU:HYL
Watchlist
Price: 5.34 EUR 0.75% Market Closed
Market Cap: 149.5m EUR
Have any thoughts about
Hyloris Pharmaceuticals SA?
Write Note

Hyloris Pharmaceuticals SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hyloris Pharmaceuticals SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Hyloris Pharmaceuticals SA
XBRU:HYL
Revenue
€2.1m
CAGR 3-Years
128%
CAGR 5-Years
87%
CAGR 10-Years
N/A
Ucb SA
XBRU:UCB
Revenue
€5.3B
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Financiere de Tubize SA
XBRU:TUB
Revenue
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hyloris Pharmaceuticals SA
Glance View

Market Cap
149.5m EUR
Industry
Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.

HYL Intrinsic Value
4.28 EUR
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Hyloris Pharmaceuticals SA's Revenue?
Revenue
2.1m EUR

Based on the financial report for Dec 31, 2023, Hyloris Pharmaceuticals SA's Revenue amounts to 2.1m EUR.

What is Hyloris Pharmaceuticals SA's Revenue growth rate?
Revenue CAGR 5Y
87%

Over the last year, the Revenue growth was 132%. The average annual Revenue growth rates for Hyloris Pharmaceuticals SA have been 128% over the past three years , 87% over the past five years .

Back to Top